About Summit Therapeutics Sub
Summit is committed to leadership in resolving serious, unmet medical needs in oncology for the betterment of overall HUMAN HEALTH. Stifel Fireside Chat Patients & Caregivers Summit Latest News Committed to Optimizing Human Health Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly
31 Job openings in Summit Therapeutics Sub
CMC Manager Drug SubstanceLocation: Onsite - Menlo Park CA Miami FL Princeton NJ or Oxford UKOverview of Role:The CMC Manager Drug Substance will play a crucial role in supporting the Director CMC Drug Substance. This position involves managing and overseeing the Chemistry Manufacturi More...
Senior Manager, Clinical Data Scientist
170000 - 190000
Location: On-Site 4 days per week at our Menlo Park CA officeOverview of Role: Summit is looking for a highly motivated Sr. Manager/ Principal Clinical Data Scientist to join our growing team. This role will play a critical part in advancing our technology and data-driven clinical dat More...
Associate Director, Facility Management
168000 - 180000
ASSOCIATE DIRECTOR FACILITY MANAGMENT Location: Palo Alto CA About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated wi More...
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays More...
Senior Manager, It Security, Compliance & Infrastructure
153000 - 180000
Sr. Manager IT Security Compliance & InfrastructureLocation: Onsite in Palo Alto CA or Princeton NJ About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with More...
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays u More...
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays More...
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays More...
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays More...
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab display More...
Senior Financial Analyst (r&d Finance/accounting)
134000 - 155000
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab display More...
Overview of Role: We are seeking a proactive and detail-oriented Corporate Paralegal to join our quickly growing team at a publicly traded company. This role provides support across corporate governance securities compliance contracting and other general corporate addition they will More...
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays More...
**THIS POSITION WILL BE ON-SITE AT OUR MIAMI FL OFFICE or MENLO PARK CA OFFICE**About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesi More...
Senior Director, Cmc Strategy Development & Delivery
221000 - 277000
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays More...
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays u More...
Job Title: Accounting Manager R&DDepartment: FinanceLocation: Menlo Park CA ONSITEJob Type: Full-Time ACCOUNTING MANAGER R&D About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy More...
LOCATION: Position will be on-site in Menlo Park CA or Princeton NJAbout Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associa More...
Associate Director, Clinical Operations
168500 - 198500
Location: On-Site 4 days per week at ourMenlo Park CA Princeton NJ or Miami FL officeAbout Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis More...
Manager, Clinical Study Start Up (contract)
50 - 60
*THIS IS A TEMPORARY POSITION*About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single More...
